J
Juliana Mendes Rocha
Researcher at University of São Paulo
Publications - 17
Citations - 203
Juliana Mendes Rocha is an academic researcher from University of São Paulo. The author has contributed to research in topics: Medicine & Hallucinogen. The author has an hindex of 3, co-authored 11 publications receiving 53 citations.
Papers
More filters
Journal ArticleDOI
Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials
Rafael G. dos Santos,Rafael G. dos Santos,Francisco S. Guimarães,Francisco S. Guimarães,José Alexandre de Souza Crippa,José Alexandre de Souza Crippa,Jaime Eduardo Cecílio Hallak,Jaime Eduardo Cecílio Hallak,Giordano Novak Rossi,Juliana Mendes Rocha,Antonio Waldo Zuardi,Antonio Waldo Zuardi +11 more
TL;DR: Evaluated SAEs related to CBD in RCT are mainly elevated transaminases, convulsion, sedation, lethargy, and upper respiratory tract infections that are related to concomitant clobazam use and should be monitored when using CBD concomitantly with these and other antiepileptic drugs.
Journal ArticleDOI
Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature:
Juliana Mendes Rocha,Flávia de Lima Osório,José Alexandre de Souza Crippa,José Carlos Bouso,Giordano Novak Rossi,Jaime Eduardo Cecílio Hallak,Rafael G. dos Santos +6 more
TL;DR: Serotonergic hallucinogens reduced the recognition of negative emotions by modulating amygdala activity and modulated amygdala activity to these stimuli, which was correlated with antidepressive effects in patients.
Journal ArticleDOI
The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges.
Rafael G. dos Santos,Rafael G. dos Santos,José Carlos Bouso,Juliana Mendes Rocha,Giordano Novak Rossi,Jaime Eduardo Cecílio Hallak,Jaime Eduardo Cecílio Hallak +6 more
TL;DR: In this paper, the authors explore some of the possible health policy challenges to integrate these therapeutic tools into broad and heterogeneous health systems, and highlight the need for an urgent dialogue between science, health system, society, and politics.
Journal ArticleDOI
Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder: A Pilot, Proof-of-Concept, Randomized, Placebo-Controlled Trial.
Rafael G. dos Santos,Flávia de Lima Osório,Juliana Mendes Rocha,Giordano Novak Rossi,José Carlos Bouso,Lucas S. Rodrigues,Gabriela de Oliveira Silveira,Mauricio Yonamine,Jaime Eduardo Cecílio Hallak +8 more
TL;DR: Ayahuasca is a classic hallucinogen with anxiolytic and antidepressive properties as discussed by the authors, which has been shown to improve speech performance and anxiety in individuals with social anxiety disorder.
Journal ArticleDOI
Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study
Dóra Révész,Genís Ona,Giordano Novak Rossi,Juliana Mendes Rocha,Rafael G. dos Santos,Rafael G. dos Santos,Jaime Eduardo Cecílio Hallak,Jaime Eduardo Cecílio Hallak,Miguel Ángel Alcázar-Córcoles,José Carlos Bouso +9 more
TL;DR: In this paper, the authors assess the impact of lifetime psychedelic drug use on mental health in relation to the first strict lockdown adopted by various countries (April-July 2020) and find that regular users of psychedelic drugs had less psychological stress and some personality differences.